Weekly exenatide controlled blood sugar; Medtronic seeks pump partners;

> A once-weekly formulation of exenatide-controlled blood glucose in Japanese diabetics is in a study sponsored by Amylin (now acquired by Bristol-Myers Squibb [$BMY]) and collaborator Eli Lilly ($LLY). The researchers designed the trial to provide data for submissions in Asia--the previous studies were carried out in non-Asian populations. Article

> Medtronic ($MDT) is seeking pharma partners to pair its pump technology with Alzheimer's disease treatments. Article

> Aegis Therapeutics has been awarded a patent for a fast-acting formulation for triptans for migraine. Press release

> Vivus ($VVUS) has launched Qsymia, a phentermine and topiramate extended-release formulation for weight management. Press release

And Finally… Cuban researchers are developing nanoparticle drugs, including a lower dose version of cyclosporine. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.